The clinical problem is formidable. Bone defects caused by trauma, infection, tumour resection and congenital abnormalities are common, and while small injuries heal spontaneously, defects exceeding the local regenerative capacity, so-called critical-sized defects, often fail to close on their own. Autologous bone grafting remains the gold standard because it delivers osteogenic cells, inductive growth factors and a conductive matrix simultaneously, but it is limited by donor-site morbidity and restricted availability. Allografts are more available yet carry risks of immune rejection, infection and variable efficacy. What is needed, the review contends, are regenerative strategies that remain stable and reproducible inside the messy, inflamed microenvironment of a real defect.

Bioprinting offers an unusual degree of control over that environment. Unlike conventional fabrication, printing allows multiple materials, cells and bioactive signals to be arranged in three dimensions with defined pore architecture, compositional gradients and localised mechanical properties. Composite bioinks built from printable hydrogels such as gelatin methacryloyl (GelMA), alginate and hyaluronic acid methacrylate can be blended with inorganic phases including calcium phosphate, hydroxyapatite, beta-tricalcium phosphate and bioactive glass, balancing printability with an osteogenic milieu. Crucially, these same components release ions and present surface chemistry that shape the earliest host immune recognition of the implant, making the printer a tool for immunology as much as for structural engineering.

The biological rationale comes from the now well-established field of osteoimmunology. Bone repair unfolds in overlapping phases: an inflammatory phase dominated by neutrophils and pro-inflammatory M1-like macrophages that clear debris and pathogens; a proliferative phase in which macrophages shift toward reparative M2-like states, releasing factors such as TGF-beta and VEGF that recruit mesenchymal stem cells and drive angiogenesis; and a remodeling phase in which osteoblasts and osteoclasts, governed by the RANKL/OPG axis, convert woven bone into mechanically adapted lamellar bone. Simply suppressing the early inflammatory burst, the review stresses, can starve the repair process of the very signals that initiate cell recruitment and vascularisation. The goal instead is controlled, resolvable inflammation.

Material composition is one of the three main levers the authors identify. Strontium-substituted calcium silicate hydrate nanowires incorporated into a GelMA bioink, for example, released Sr, Ca and Si ions that nudged macrophages toward a repair-associated phenotype while supporting bone marrow stromal cell differentiation, producing substantial regeneration in rat critical-sized calvarial defects. Silicon-substituted calcium phosphate combined with methacrylated bone-derived extracellular matrix showed a striking temporal immune transition in vivo, from early pro-inflammatory activation to later anti-inflammatory resolution, linked to suppression of p38 MAPK signalling. Zinc-releasing ZIF-8 metal-organic framework particles delivered the anti-inflammatory polyphenol luteolin alongside Zn2+ ions, integrating immunomodulation, antioxidation and antibacterial action in a single printed construct.

Geometry itself can be immunologically active. Using digital light processing, researchers fabricated hydroxyapatite scaffolds identical in composition but differing only in pore size, and found that 600-micrometre pores best regulated macrophage behaviour through IFN-beta and HIF-1alpha-related signalling while improving vascularisation and bone formation. Even curvature matters: beta-tricalcium phosphate scaffolds engineered with negative Gaussian curvature suppressed macrophage Ras-MAPK/HIF-1alpha signalling and increased secretion of BMP-2 and VEGF, promoting vascularised bone ingrowth in a rabbit segmental defect model. Melt electrowriting adds another dimension, with ordered PCL microfibres and calcium phosphate coatings steering macrophages toward repair-associated states via PI3K/AKT and cAMP-PKA signalling, demonstrating that physical microarchitecture can substitute for exogenous drugs.

The most sophisticated strategies deliver bioactive cargo in stage-matched sequences. One printed system used coaxial bioprinting with sequential crosslinking to release interferon-gamma first, preserving the early inflammatory activation needed for repair initiation, before Laponite-derived magnesium and silicon ions gradually drove macrophages toward a reparative state, ultimately enhancing vascularised bone regeneration in calvarial defects. Interleukin-4 delivered from graphene oxide/black phosphorus nanointerfaces promoted CD206-positive macrophages while the materials themselves supported angiogenesis and osteogenesis. Exosome-based approaches add further nuance: macrophage-derived vesicles from mixed functional states outperformed those from purely M2-like macrophages in stimulating osteogenic signalling, underscoring the review’s warning that the simplified M1/M2 dichotomy cannot capture the continuum of immune states that real healing involves.

The authors are candid about translational hurdles. Every added component, whether living cells, recombinant cytokines, exosomes or decellularised matrix, increases batch variability, manufacturing complexity and regulatory burden. Sterilisation methods can silently alter hydrogel mechanics and even macrophage gene expression, while endotoxin contamination at low levels can confound the interpretation of a material’s intrinsic immunological effects. Degradation kinetics must be synchronised with tissue ingrowth: too fast and the scaffold loses support prematurely, too slow and the foreign-body response persists. The review advocates defining critical quality attributes that reflect immunomodulatory potency, not just scaffold geometry and compressive strength, and pursuing standardised platforms with patient-specific variation confined to a validated design space.

Looking forward, the field is moving toward spatiotemporal and even intelligent regulation. Microenvironment-responsive hydrogels that release therapeutic ions only under pathological acidity or oxidative stress, four-dimensional printing that changes scaffold architecture over time, and machine-learning frameworks that optimise bioink composition against immune as well as mechanical endpoints all feature in the review’s roadmap. Pathology-specific design receives particular emphasis: infected defects need preserved antimicrobial inflammation before resolution, diabetic defects require correction of hyperglycaemia-driven oxidative stress, and aged or osteoporotic bone demands restoration of senescence-impaired immune function rather than generic osteogenic stimulation. The overarching message is that the next generation of bone scaffolds should not simply contain more ingredients, but should speak the immune system’s own temporal language, guiding inflammation, vascularisation and remodeling in the order that nature intended.

Subject of Research: Immunoregulatory biomaterials and 3D bioprinting strategies for bone regeneration

Article Title: Advances in 3D bioprinting of immunoregulatory biomaterials for bone regeneration

Article References: Wang, X., & Zhang, A. (2026). Advances in 3D bioprinting of immunoregulatory biomaterials for bone regeneration. Materials Today Bio, 41, Article 103714. https://doi.org/10.1016/j.mtbio.2026.103714

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103714

Keywords: 3D bioprinting, bone regeneration, osteoimmunology, macrophage polarization, bioinks, GelMA, biomaterials, critical-sized bone defects, exosomes, cytokine delivery, scaffold architecture, tissue engineering

The problem the researchers set out to solve is deceptively simple to state. In tissue engineering, scaffolds are the porous structures that support cell attachment and guide new tissue formation, and in craniofacial applications, where surgeons aim to reconstruct complex bones of the skull and face, the pore size, shape and spatial distribution of a scaffold are decisive for regenerative success. Additive manufacturing has made it possible to print scaffolds with predefined porosity, but what comes out of the printer does not always match what went into the design file. Bioinks, the cell-laden hydrogel mixtures used in bioprinting, can shear, spread or rearrange during extrusion, degrading shape fidelity. Verifying the printed result has traditionally meant laborious manual image analysis in software such as ImageJ or CellProfiler, an approach that is slow and, crucially, vulnerable to user bias.

The new platform couples custom 3D-printed hardware with a dedicated image-processing pipeline written in MATLAB. The imaging rig consists of a 12.3-megapixel Raspberry Pi High Quality Camera built around the Sony IMX477 sensor, fitted with a 6 mm wide-angle CS-mount lens and mounted on an adjustable 3D-printed monopod. A NeoPixel 12-LED RGB ring, held in a flexible thermoplastic polyurethane adapter, bathes the sample in homogeneous white light against a high-contrast black-and-white background, sharpening the contours of scaffold edges and suppressing the shadows that would otherwise corrupt segmentation. A Raspberry Pi 3 Model B+ and an Arduino Uno handle communication between the camera, the lighting and the host computer, and the structural parts of the mount were printed in polylactic acid, the workhorse polymer of desktop 3D printing.

The software side is where the engineering becomes genuinely distinctive. The pipeline takes a single zenithal image of the scaffold and processes it through a fixed sequence of operations: rotation, correction of the barrel distortion introduced by the wide-angle lens using a radial distortion model with an empirically determined coefficient of −0.15, grayscale conversion, interactive cropping, and automated segmentation by Otsu’s global thresholding, which chooses the black-and-white cutoff that maximises inter-class variance in the image histogram. Connected-component labelling with 8-connectivity then identifies each pore, and blob analysis filters out objects that are too small or too large to be genuine pores. The system outputs the number, area, perimeter and compactness of every pore in the uppermost printed layer, exporting the results to a spreadsheet alongside an annotated overlay image.

One of the most elegant technical contributions is the compactness metric. Rather than using the classical isoperimetric quotient, which anchors a circle at unity, the authors square-normalise the measure so that a perfect square pore scores exactly one, matching the orthogonal geometry that most printed scaffolds are designed to have. A penalty function then converts deviations in either direction, pores that round off or become convoluted, into a percentage quality score between 0 and 100 percent, with a perfect square yielding 100 percent and a perfectly circular pore scoring 72.7 percent. The authors note that their metric is the reciprocal of the printability index commonly used to assess bioink shape fidelity, which allows their values to be compared directly with the existing bioprinting literature. A colour-indexed graph maps each pore’s score onto a gradient, giving researchers an at-a-glance map of where a print went wrong.

The validation strategy was deliberately staged across four assays. First, a printed reference grid with known 0.5 cm square cells established the system’s trueness and repeatability. The platform proved remarkably repeatable, with a coefficient of variation of just 1.33 percent, but it systematically underestimated pore area by 11.6 percent, measuring a mean of 0.221 square centimetres against a nominal 0.250. The authors trace this bias to the manual pixel-per-centimetre calibration and to the segmentation threshold placing the detected edge slightly inside the true pore boundary. Because the error is systematic and reproducible, it can be removed by calibrating against a reference of certified area, a straightforward fix that turns a flaw into a documented, correctable offset.

The second assay delivered the headline comparison. On a 3D-printed polylactic acid scaffold containing three classes of pores, five repeated acquisitions by the platform agreed to within a coefficient of variation of 0.01 to 2.48 percent. The same specimen was then measured manually by three experienced tissue engineering researchers, and the results were striking: inter-user coefficients of variation ranged from 11.5 to 22.8 percent, and intra-user variability from 0 to 12.7 percent. Counterintuitively, the manual measurements diverged most on the larger pores, the opposite of the pixel-resolution sensitivity shown by the automated system on small features. The authors argue this exposes a systemic problem in collaborative laboratories, where measurement quality depends on individual attention and experience, and where dispersion between operators can exceed an order of magnitude.

Feasibility was then demonstrated on materials far harder to image than rigid plastic. Two self-setting silica–gelatin hybrid bioinks, differing only in their gelatin-to-sol volume ratio, were printed into 16-pore scaffolds on a Cellink BioX bioprinter; because the inks are transparent, they were dyed with methylene blue to create contrast. The software successfully segmented the complex, non-linear pore boundaries of these hydrated hydrogel constructs, where manual measurement is most error-prone, and revealed a printing resolution error of 0.0051 square centimetres relative to the design ground truth. A final assay on a brittle silica-based scaffold showed the compactness output flagging shape deviations that the printer’s settings were supposed to prevent. The authors are careful to note that these last assays were feasibility demonstrations without independent reference measurements, not full accuracy validations.

The platform does not attempt to replace micro-computed tomography, the gold standard for resolving a scaffold’s internal three-dimensional architecture, pore interconnectivity and through-thickness geometry. Micro-CT remains expensive, slow, with acquisition and reconstruction reaching 19.5 hours and 166 gigabytes per specimen at the finest pixel sizes, and it introduces dehydration and staining artefacts in hydrated hydrogels. The optical platform instead quantifies the two-dimensional projected macrotopography of the top printed layer, positioning itself as a rapid, non-destructive screening complement to volumetric imaging. Its limitations are candidly acknowledged: the workflow is semi-automated, with focus, aperture, monopod height, illumination and crop region set by the operator, the distortion coefficient must be redetermined for any different optical configuration, and low-contrast specimens may require staining.

What makes the work resonate beyond its immediate niche is its accessibility. The entire bill of materials comes to approximately €170 excluding VAT, the source code and 3D-printable STL files are openly available under an MIT licence, and the pipeline relies only on standard image-processing primitives, meaning it can be reproduced without a commercial MATLAB licence using GNU Octave or Python with OpenCV. By demonstrating that repeatability can be made independent of operator experience, the team offers laboratories a practical route to objective quality control in scaffold fabrication. The authors emphasise that no craniofacial-specific or clinical specimen was evaluated in this study, and that establishing utility in that demanding setting will require dedicated validation. But as patient-specific scaffolds for skull and facial bone reconstruction move closer to the clinic, the ability to verify, cheaply and reproducibly, that what was printed matches what was designed is exactly the kind of unglamorous infrastructure that turns promising biofabrication into reliable medicine.

Subject of Research: A low-cost semi-automated imaging platform for quantitative characterisation of 3D-printed scaffold surface macrotopography in tissue engineering

Article Title: A low-cost imaging platform for quantitative characterisation of scaffold surface macrotopography with potential application in craniofacial tissue engineering

Article References: Marimon, X., Saman-Sakkal, E., Rodriguez, R., Portela, A., Cerrolaza, M., Mateos, M. A., & Pérez, R. (2026). A low-cost imaging platform for quantitative characterisation of scaffold surface macrotopography with potential application in craniofacial tissue engineering. Medical & Biological Engineering & Computing. https://doi.org/10.1007/s11517-026-03661-6

Image Credits: AI Generated

DOI: 10.1007/s11517-026-03661-6

Keywords: tissue engineering, scaffolds, 3D printing, bioprinting, image processing, pore analysis, craniofacial regeneration, Raspberry Pi, shape fidelity, quality control, bioinks, computer vision

The authors argue that the term bone organoid has been applied far too loosely. Spheroids, which are useful modular building blocks that can enhance osteogenic differentiation, often lack tissue-level organization altogether. Engineered constructs can reproduce geometry or mechanical behavior yet remain dominated by an exogenous scaffold rather than by cells. Under the framework proposed in the review, a genuine bone organoid must satisfy four core criteria: it must be a viable cell-derived three-dimensional tissue that develops organization beyond simple aggregation; it must produce its own collagenous or osteoid-like matrix with spatially and temporally resolved mineralization; it must show that new mineral is biologically deposited rather than inherited from the material it was grown on; and it must display at least one dynamic skeletal function, such as regulated matrix formation, formation-resorption coupling or a controlled mechanobiological response. Engineered guidance is permitted, but only when it is transient or demonstrably permissive to endogenous organization.

The review goes further by proposing a tiered classification system with five categories: osteogenic spheroids, bone-like microtissues, engineered skeletal constructs, bone organoids and high-fidelity bone organoids. The top designation demands evidence across three interdependent domains. Structural mimicry requires hierarchical extracellular matrix organization and progressive mineralization that mirrors the sequence seen in native bone, where cells first deposit unmineralized osteoid and mineral then advances from discrete fronts. Functional fidelity requires coupled activity between osteoblast-lineage cells that build matrix and osteoclast-lineage cells that resorb it, linked through signaling pathways such as RANKL, RANK and osteoprotegerin. Biomechanical integrity requires that the construct maintain structural coherence and exhibit measurable mechanosensation, reflecting the fact that bone cells continuously convert mechanical loading, fluid flow and matrix stiffness into biological responses. Crucially, the authors stress that a sophisticated scaffold-dominated construct can be clinically useful while still falling outside the organoid class; placement is a statement about the source of organization, not about quality.

When the authors applied this classification to representative original studies, the results were sobering. Of the ten studies examined in their evidence map, several constructs labeled organoids by their original authors were reassigned as osteogenic spheroids because self-assembly was limited to the spheroid unit and tissue-level hierarchy was never demonstrated. Others were reclassified as engineered skeletal constructs because pre-existing material architecture dominated organization. Only a handful, including a 2021 woven bone organoid grown from human bone marrow stromal cells and a 2025 system using dynamic dual-network hydrogels in which cell migration generated spatiotemporal woven-bone architecture, met the core organoid criteria. Notably, no current model satisfies every high-fidelity domain, and the reviewers conclude that transparent reporting of what was tested, and what was not, is essential for the field to advance.

A recurring problem the review highlights is confounding between biological mineralization and material-derived mineral signals. Many popular bone engineering strategies incorporate nano-hydroxyapatite, bioactive glass or black-phosphorus nanosheets that release phosphate ions, and any of these can generate calcium deposits that look like bone formation on a stain but are actually chemical precipitation. The framework therefore demands that active, biologically regulated mineralization be distinguished from material contributions using acellular baselines, a requirement that several widely cited nanomaterial-based studies do not currently meet. The authors also emphasize that late osteogenic marker expression alone does not establish functional bone-like tissue; marker data must be interpreted alongside matrix organization and mineral distribution.

Beyond classification, the review provides a detailed account of the biology that a faithful model must capture. Osteoblasts deposit type I collagen-rich osteoid that later mineralizes as hydroxyapatite crystals grow; a subset of these cells becomes embedded as osteocytes, which sense strain through dendritic processes in canalicular networks and regulate both building and resorption through mediators such as sclerostin. Osteoclasts, formed by fusion of monocyte-macrophage precursors, acidify the resorption compartment and release enzymes that remove mineral and collagen while also releasing matrix-stored growth factors like TGF-beta and BMP-related signals. Meanwhile, endothelial cells provide angiocrine signaling that supports osteoprogenitor maintenance, and neural elements release calcitonin gene-related peptide and substance P, which influence osteoblast, osteoclast and vascular function. The review cautions that multilineage marker expression alone is insufficient; functional integration must be demonstrated with lineage-appropriate readouts such as lumen formation and perfusion for vessels, or innervation-dependent regulation of remodeling for nerves.

On the fabrication side, the authors take a clear-eyed view of bioprinting, distinguishing between printing preformed organoids and printing for organoid formation, with only the former deserving the label unless post-print self-organization is demonstrated. They survey the four major modalities: inkjet printing offers fine patterning but limited viscosity range, extrusion printing handles mineral-filled bioinks and is the most scalable but exposes cells to shear stress, laser-assisted printing achieves micrometer-scale nozzle-free patterning but is limited by throughput, and light-based stereolithography and digital light processing generate complex channels but suffer from optical attenuation in mineral-rich inks. Across all modalities, the review finds that evidence that printing improves organoid maturation remains substantially weaker than evidence that it improves initial geometry. Hybrid strategies, such as temporary scaffold-guided self-assembly, printed channels coupled with self-organized microvasculature, and modular assembly of developmentally primed cartilage microtissues, are highlighted as the most promising path forward, exemplified by recent bioprinted bone-organoid grafts with guided vascularization that matured after implantation.

The translational outlook is cautiously encouraging. Patient-derived chondrosarcoma organoids have faithfully recapitulated histological and genetic features of parental tumors and shown sensitivity to the SHH pathway inhibitor vismodegib, while a biobank of 44 sarcoma organoid lines has enabled high-throughput drug screening. A three-dimensional vascularized humanized bone organoid has revealed that estrogen withdrawal drives vessel-like structure formation and mineral deposition, offering mechanistic insight into postmenopausal osteoporosis that non-vascularized models could not capture. Induced pluripotent stem cell-derived jawbone organoids have reproduced phenotypic features of osteogenesis imperfecta, pointing toward precision modeling of genetic skeletal disease. For regenerative applications, engineered ossification center-like organoids and periosteum-derived organoids combined with printed scaffolds have achieved bone repair in rodent critical-sized defects, though the authors note that systematic comparison against autograft controls remains an essential next step.

The review closes with a series of practical proposals intended to move the field from anecdote to standard. These include a minimum reporting checklist covering cell source, passage number, matrix composition, induction schedules, regional rather than whole-construct viability, quantitative mineralization assessment and predefined exclusion criteria for poorly formed organoids, together with application-specific potency assays: coupled remodeling endpoints for osteoporosis models, reproducible dose-response data for drug screening platforms and vascularized bone formation for regenerative grafts. The authors also flag regulatory hurdles, noting that clinical-grade organoids will require good manufacturing practice compliance, validated potency assays and jurisdiction-specific pathways such as the European Advanced Therapy Medicinal Product framework. Their overarching message is that progress will come not from adding complexity indiscriminately but from controlling when and where complexity is introduced, with stimuli-responsive matrices that yield to endogenous tissue, machine-learning-optimized printing and microfluidic platforms that connect bone organoids to vascular, immune and metabolic modules. Bone organoids, the review concludes, occupy a genuinely valuable intermediate position between dish and animal, provided the label is reserved for constructs that can prove they deserve it.

Subject of Research: Development of an operational classification framework and biofabrication standards for engineering high-fidelity bone organoids

Article Title: Engineering high-fidelity bone organoids: Operational classification, multilineage crosstalk, biofabrication evidence, and translational validation

Article References: Huang, Y., Zhang, T., Chen, S., Zhou, H., Xu, H., Zhang, F., Li, L., & Lyu, F. (2026). Engineering high-fidelity bone organoids: Operational classification, multilineage crosstalk, biofabrication evidence, and translational validation. Materials Today Bio, 41, Article 103676. https://doi.org/10.1016/j.mtbio.2026.103676

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103676

Keywords: bone organoids, organoid classification, bioprinting, osteoblasts, osteoclasts, mineralization, vascularization, hydrogels, disease modeling, drug screening, bone regeneration, bioinks

The problem the Allstruder addresses is well known to anyone working in bioprinting, food printing, soft robotics, or electronics fabrication. Commercial extrusion systems generally fall into two camps, each with a fundamental compromise. Volumetrically accurate syringe pumps deliver precise doses but respond sluggishly, while pressure-based syringe extruders build pressure quickly but sacrifice precision. Both categories tend to be expensive, difficult to customize, and poorly matched to the open, modular workflows that dominate academic and educational settings. The result, the authors argue, is a technical barrier that drives labs to build in-house hardware for the same unmet need over and over, undermining reproducibility and accessibility across the community. A graduate student, they note, should not have to spend months developing a bespoke extruder simply to print a new bioink.

The do-it-yourself landscape has not solved this fragmentation. The rise of affordable desktop thermoplastic printers has inspired dozens of creative open-source fluid extrusion designs, but nearly all are tailored to specific materials, machines, or niches, and few generalize across use cases, users, and environments. Labs frequently tailor their workflows to the constraints of a particular extruder, locking themselves into siloed methodologies that limit interoperability and shared progress. Several prior designs nonetheless stand out as foundational. The Replistruder series brought affordable, precise, retractable syringe extrusion to embedded FRESH bioprinting and became the most widely cited and remixed open extruder family, with the Replistruder 3 setting benchmarks for accessibility, the Replistruder 4 adding off-the-shelf metal parts for reliability, and the Replistruder 5 pushing toward high-performance, multi-material use. The Large Volume Extruder handled 50 mL syringes for bulkier pastes such as clays, the Enderstruder converted the ubiquitous Creality Ender 3 into a capable fluid printer at minimal cost, and the pioneering Fab@Home platforms introduced early direct ink writing and extruder retraction concepts.

To evaluate these predecessors systematically, the team developed a five-metric framework covering affordability, performance, simplicity, versatility, and design for 3D printing, decomposing each metric into measurable sub-criteria and scoring every device against them. The published rubric reveals a pattern of deliberate trade-offs rather than failures. The Replistruder 3 scored well on affordability and performance but poorly on simplicity because it demanded considerable expertise. The Replistruder 4 traded fully printed construction for the stiffness of aluminum and steel, gaining performance while preserving accessibility. The Replistruder 5 ranks highest in mechanical performance because it is optimized entirely around premium glass syringes and a narrow, high-quality configuration, which is precisely why it scores lower on versatility and affordability. The Enderstruder maximizes simplicity for a single popular printer, while the Large Volume Extruder accepts a resolution ceiling in exchange for large volumes of low-cost material. No prior tool, the analysis shows, occupies the center of the design space.

The Allstruder was engineered to do exactly that: remain broadly capable across all five metrics simultaneously, with particular attention to the simplicity and versatility gaps left by existing designs. Mechanically, it divides into four main sections. The actuator consists of a 3D-printed frame housing a leadscrew-driven pusher block guided along a precision linear rail, with the leadscrew supported by ball bearings at both ends for smooth, stable motion. Two frame sizes offer stroke lengths of 66 and 116 millimeters. The transmission, housed in a printed motor mount, uses a fiber-backed 2GT timing belt to couple a NEMA 14 or NEMA 17 stepper motor to the leadscrew, with slotted mounting holes allowing straightforward belt tensioning and backlash reduction. A keyed slot on the pusher block mates with a boss on each syringe adapter, guaranteeing correct realignment every time a syringe is swapped.

That adapter system is the heart of the device’s material and machine agnosticism. Paired printed adapters, one gripping the syringe plunger and one holding the barrel, allow the Allstruder to accept reusable gastight glass syringes from 0.1 to 25 mL and disposable plastic syringes from 3 to 100 mL, positioning each syringe as close as possible to the actuator to minimize deflection and positional error. The growing component ecosystem includes two frames, two motor mounts, two pusher blocks, twelve syringe adapters, a Bowden nozzle adapter, a syringe heater for materials like chocolate, and more than ten printer mounts. Three example configurations illustrate the range: a balanced base setup with a 2.5 mL glass syringe; a large-volume Bowden arrangement using a 50 mL syringe and extended frame, mounted to the printer frame with extrusion delivered through tubing; and an extreme-precision build pairing a 0.1 mL glass syringe with anti-backlash components and a 0.9-degree stepper motor for fine control of precious inks.

Physical design choices reflect the demands of high-speed, multi-material printing. Four widely spaced mounting bolts secure the extruder firmly to a printer’s gantry, and a deliberately low center of mass minimizes vibration and wobble from inertia during sharp directional changes, much like a wide-wheelbase racing car. The motor, the widest component, sets the overall width at roughly 44 millimeters, allowing multiple Allstruders to be arrayed densely for multi-material work or spaced apart for applications such as printing into petri dishes. The platform supports direct drive and Bowden-style setups, coaxial extrusion, high-pressure, high-resolution, and high-speed configurations. Assembly requires only metric Allen wrenches and standard bolts, proceeds largely in a single plane, and is documented in step-by-step video guides. Printed parts are optimized for PETG on standard FFF machines, refined through more than 85 iterations aimed at improving first-print success rates, with PCTG and certain photopolymer resins also validated.

Validation was conducted through a distributed network of laboratories using different materials, printers, and skill levels, with iterative feedback used to eliminate adoption-limiting issues. The device has been fitted to more than twelve popular printers and bioprinters, ranging from Creality Ender 3 V2 machines to a CellInk INKREDIBLE, and was adapted to the Printess, a low-cost open-source bioprinter from the Skylar-Scott lab, via a custom mount. Mechanically, a dial-indicator test pressurizing a 5 mL plastic syringe to 30 PSI above ambient, a pressure exceeding what most bioinks require, measured a maximum pusher deflection of just 20 micrometers at a calculated force of 24 newtons, quantifying the rigidity of the drive mechanism itself. In a representative print test on a Creality K1 SE using a 1 mL glass syringe, 23 mg/mL Type I collagen, and a 30-gauge needle, printed collagen filaments averaged 141.8 micrometers in width against a 150-micrometer needle, with center-to-center spacing errors below 3 percent and between-filament spacing errors under 4 percent, results the authors attribute largely to the host printer and syringe rather than the extruder.

Beyond printing, the team envisions the Allstruder as shared infrastructure with uses well beyond its original community. Researchers can move between embedded FRESH printing and direct ink writing across bioinks, hydrogels, ceramic and aerogel precursors, edible materials, conductive inks, and silicones on a single reconfigurable head. Hardware developers can treat it as a stable, well-characterized base for custom syringes, heaters, chillers, manifolds, active mixing heads, and valved dispensers. Labs with heterogeneous printer fleets can standardize on one extrusion platform, making protocols portable between machines and institutions. The actuator can even serve as a programmable, printer-controlled syringe pump for reagent metering or fabricating assay substrates such as immunochromatographic test strips, and it functions as a low-cost, openly documented linear stage for general precision-motion tasks. At roughly 50 dollars per unit, it has already been used in workshops worldwide where commercial syringe-extrusion systems would be cost-prohibitive, lowering the barrier to hands-on education in additive manufacturing and biofabrication.

The Allstruder’s release arrives amid growing calls for standardization in extrusion-based bioprinting, where round-robin studies have highlighted how difficult reproducibility remains across labs. By consolidating lessons from a decade of open-source extruder development into one adaptable, rigorously characterized platform, its creators hope to shift community effort away from reinventing actuation and toward the science the hardware enables. The device does not outperform a purpose-built tool within that tool’s own niche, the authors are careful to note, but it delivers strong performance while remaining easier to use and more broadly compatible, making it the more practical option for most users and applications. In that balance, a mechanism rigid enough that print fidelity is limited only by the user’s choice of syringe and printer, offered freely and inexpensively, the Allstruder aims to become the common foundation for the next generation of syringe-based printing.

Subject of Research: An open-source, low-cost syringe pump extruder enabling versatile fluid and biomaterial 3D printing on standard desktop printers.

Article Title: The Allstruder: an open syringe extruder for every 3D printer

Article References: Hinton, T., Patten, R., PereiraTavares, A. J., Crosby, C., & Shiwarski, D. J. (2026). The Allstruder: an open syringe extruder for every 3D printer. HardwareX, 28, Article e00827. https://doi.org/10.1016/j.ohx.2026.e00827

Image Credits: AI Generated

DOI: 10.1016/j.ohx.2026.e00827

Keywords: open-source hardware, syringe extruder, 3D bioprinting, FRESH printing, direct ink writing, bioinks, additive manufacturing, HardwareX, hydrogels, low-cost bioprinter, reproducibility, CERN OHL